Review: taking Depakote er and Keppra together


Summary

Drug interactions are reported among people who take Depakote er and Keppra together. This review analyzes the effectiveness and drug interactions between Depakote er and Keppra. It is created by eHealthMe based on reports of 1,030 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Depakote er and Keppra >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Depakote Er

Depakote er has active ingredients of divalproex sodium. It is often used in bipolar disorder. (latest outcomes from Depakote er 3,883 users)

Keppra

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. (latest outcomes from Keppra 24,568 users)

On Aug, 18, 2016

1,030 people who take Depakote Er, Keppra are studied.


Number of reports submitted per year:

Depakote er and Keppra drug interactions.

Drug effectiveness over time:

Depakote Er:
  • < 1 month: 100.0% - (1 of 1 people)
  • 1 - 6 months: 25.0% - (1 of 4 people)
  • 6 - 12 months: 0.0% - (0 of 4 people)
  • 1 - 2 years: 50.0% - (3 of 6 people)
  • 2 - 5 years: 14.0% - (1 of 7 people)
  • 5 - 10 years: 87.0% - (7 of 8 people)
  • 10+ years: 66.0% - (6 of 9 people)
  • not specified: 0.0% - (0 of 1 people)
Keppra:
  • < 1 month: 50.0% - (1 of 2 people)
  • 1 - 6 months: 33.0% - (2 of 6 people)
  • 6 - 12 months: 33.0% - (2 of 6 people)
  • 1 - 2 years: 0.0% - (0 of 6 people)
  • 2 - 5 years: 36.0% - (4 of 11 people)
  • 5 - 10 years: 83.0% - (5 of 6 people)
  • 10+ years: 50.0% - (1 of 2 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Depakote Er:
  • female: 29.0% - (5 of 17 people)
  • male: 60.0% - (14 of 23 people)
Keppra:
  • female: 31.0% - (5 of 16 people)
  • male: 43.0% - (10 of 23 people)

Drug effectiveness by age:

Depakote Er:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 100.0% - (3 of 3 people)
  • 10-19: 33.0% - (3 of 9 people)
  • 20-29: 70.0% - (7 of 10 people)
  • 30-39: 37.0% - (3 of 8 people)
  • 40-49: 33.0% - (2 of 6 people)
  • 50-59: 33.0% - (1 of 3 people)
  • 60+: 0.0% - (0 of 1 people)
Keppra:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 100.0% - (2 of 2 people)
  • 10-19: 10.0% - (1 of 10 people)
  • 20-29: 55.0% - (5 of 9 people)
  • 30-39: 25.0% - (2 of 8 people)
  • 40-49: 66.0% - (4 of 6 people)
  • 50-59: 33.0% - (1 of 3 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • granulocytopenia
  • blood cholesterol increased
  • blood glucose increased
  • blood triglycerides increased
  • convulsion
  • haematocrit decreased
  • haemoglobin decreased
  • overdose
  • stevens-johnson syndrome
  • abnormal behaviour
1 - 6 months:
  • convulsion
  • pyrexia
  • drug ineffective
  • fall
  • syncope
  • deep vein thrombosis
  • pain
  • confusional state
  • grand mal convulsion
  • lethargy
6 - 12 months:
  • asthenia
  • convulsion
  • tremor
  • weight decreased
  • atrial fibrillation
  • atrophy
  • cognitive disorder
  • gait disturbance
  • memory impairment
  • postictal paralysis
1 - 2 years:
  • somnolence
  • atrophy
  • cognitive disorder
  • gait disturbance
  • memory impairment
  • postictal paralysis
  • speech disorder
  • weight decreased
  • sedation
  • abnormal behaviour
2 - 5 years:
  • convulsion
  • dizziness
  • constipation
  • asthenia
  • gait disturbance
  • grand mal convulsion
  • pancytopenia
  • tremor
  • abnormal behaviour
  • amnesia
5 - 10 years:
  • diabetes mellitus
  • convulsion
  • alopecia
  • diabetic ketoacidosis
  • pancreatitis
  • weight decreased
  • aggression
  • chest pain
  • speech disorder
  • tremor
10+ years:
  • memory impairment
  • somnolence
  • abnormal loss of weight
  • convulsion
  • hypoglycaemia
  • abnormal dreams
  • amnesia
  • anxiety
  • decreased appetite
  • vitamin c deficiency
not specified:
  • convulsion
  • somnolence
  • tremor
  • drug ineffective
  • dizziness
  • grand mal convulsion
  • fall
  • memory impairment
  • anxiety
  • pneumonia

Most common drug interactions by gender *:

female:
  • convulsion
  • tremor
  • dizziness
  • memory impairment
  • alopecia
  • anxiety
  • pain
  • headache
  • mental status changes
  • fall
male:
  • convulsion
  • somnolence
  • drug ineffective
  • grand mal convulsion
  • sedation
  • weight increased
  • fall
  • aggression
  • granulocytopenia
  • pneumonia

Most common drug interactions by age *:

0-1:
  • convulsion neonatal
  • drug exposure during pregnancy
  • hypersomnia
  • nuclear magnetic resonance imaging brain abnormal
  • pneumonia aspiration
  • stevens-johnson syndrome
2-9:
  • convulsion
  • aggression
  • somnolence
  • dehydration
  • lethargy
  • hallucination, auditory
  • drug ineffective
  • enuresis
  • pneumonia
  • abnormal behaviour
10-19:
  • convulsion
  • weight decreased
  • sedation
  • somnolence
  • abnormal behaviour
  • grand mal convulsion
  • dizziness
  • alopecia
  • cognitive disorder
  • fall
20-29:
  • convulsion
  • granulocytopenia
  • aggression
  • grand mal convulsion
  • confusional state
  • somnolence
  • anxiety
  • headache
  • anger
  • dysphagia
30-39:
  • convulsion
  • amnesia
  • anxiety
  • memory impairment
  • abnormal dreams
  • abnormal loss of weight
  • decreased appetite
  • hypoglycaemia
  • vitamin c deficiency
  • drug ineffective
40-49:
  • convulsion
  • mental status changes
  • somnolence
  • diabetes mellitus
  • back pain
  • weight decreased
  • aphasia
  • nausea
  • ataxia
  • chest pain
50-59:
  • convulsion
  • dizziness
  • syncope
  • deep vein thrombosis
  • pain
  • pyrexia
  • drug ineffective
  • pneumonia
  • asthenia
  • haematocrit decreased
60+:
  • convulsion
  • tremor
  • fall
  • confusional state
  • loss of consciousness
  • memory impairment
  • dizziness
  • chest pain
  • fatigue
  • hypertension

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Depakote er and Keppra?

Can you answer these questions?

More questions for: Depakote er, Keppra

You may be interested in these reviews

More reviews for: Depakote er, Keppra

On eHealthMe, Depakote er (divalproex sodium) is often used to treat bipolar disorder. Keppra (levetiracetam) is often used to treat epilepsy. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.